Chronic Inflammatory-Related Disease and Cardiovascular Disease in MESA
JACC Advances,
Journal Year:
2025,
Volume and Issue:
4(4), P. 101640 - 101640
Published: March 3, 2025
Inflammation
plays
a
role
in
cardiovascular
disease
(CVD).
We
defined
various
noncardiovascular
and
noncancer
conditions,
both
infectious
noninfectious,
with
common
basis
of
inflammation,
collectively
termed
chronic
inflammatory-related
(ChrIRD).
describe
ChrIRD
its
interplay
CVD
during
follow-up
the
Multi-Ethnic
Study
Atherosclerosis.
The
aim
study
was
to
ChrIRD,
associations
CVD,
association
mortality.
Participants
were
free
overt
at
baseline
median
17.9
(Q1-Q3:
14.9-18.6)
years
follow-up.
determined
by
review
hospitalization
death
records
International
Classification
Diseases
codes.
diagnosis
adjudicated
based
on
medical
records.
performed
time-dependent
proportional
hazard
regressions
identify
risks
related
or
events.
MESA
(Multi-Ethnic
Atherosclerosis)
participants
(n
=
6,791)
had
mean
age
62
±
10
years,
47%
(3,201/6,791)
men,
39%
(2,617/6,791)
White,
28%
(1,882/6,791)
Black,
22%
(1,489/6,791)
Hispanic,
12%
(803/6,791)
Chinese
race/ethnicity.
observed
29%
(1,965/6,791)
21%
(1,420/6,791);
including
11%
(761/6,791)
conditions.
Mortality
after
only
(567/1,204;
95%
CI:
44%-49%);
45%
(300/659;
41%-49%);
conditions
67%
(510/761;
63%-70%).
associated
increased
risk
(HR:
1.48,
1.23-1.77)
2.23,
1.97-2.52).
Baseline
inflammatory
markers
predicted
is
common,
present
all
organ
systems,
significant
mortality,
particularly
combination
CVD.
between
bidirectional,
are
Language: Английский
Absence of Standard Modifiable Risk Factors in Middle Eastern Patients with Atherosclerotic Cardiovascular Disease. The Jordan Absence of Standard Modifiable Risk Factors (SMuRF-Less) Study
Vascular Health and Risk Management,
Journal Year:
2025,
Volume and Issue:
Volume 21, P. 39 - 50
Published: Feb. 1, 2025
Background:
A
growing
number
of
individuals
develop
atherosclerotic
cardiovascular
disease
(ASCVD)
despite
the
absence
standard
modifiable
risk
factors
(hypertension,
diabetes,
dyslipidemia,
and
cigarette
smoking)
(SMuRF-less
patients).
Prevalence
SMuRF-less
patients
in
Middle
East
has
not
been
studied.
This
study
investigates
prevalence,
clinical
profiles
outcomes
compared
with
those
who
have
SMuRFs.
Methods:
We
analyzed
data
from
6
published
registries
Jordan
study,
including
baseline
demographic
features,
factors,
comorbid
diseases,
utilization
secondary
prevention
pharmacotherapy
one
year
outcome
patients,
1–
2
SMuRFs
3–
4
Results.
total
f
5540
ASCVD
were
enrolled.
Mean
age
was
57.5
±
11.6
years,
1333
(24.1%)
women.
Of
whole
group,
214
(3.9%)
SMuRF-less,
3014
(54.4%)
had
2312
(41.7%)
Compared
groups,
group
younger,
more
likely
to
be
men,
lower
prevalence
obesity,
physical
inactivity,
metabolic
syndrome,
heart
failure
chronic
kidney
disease.
less
receive
medications
(antiplatelet
agents,
statins,
renin
angiotensin
blockers
beta
blockers);
all
p
<
0.001.
One
survival
significantly
than
that
groups
(97.7%
vs.98.4%
vs.98.3%,
respectively,
=
0.01).
Multivariate
analysis
showed
young
age,
preventive
associated
better
outcome.
Conclusion:
In
this
cohort
ME
ASCVD,
nearly
four
100
SMuRF-less.
rate
is
reported
by
most
studies,
mainly
due
high
disease,
received
higher
mortality
Clinical
Trials:
The
registered
ClinicalTrials.gov,
unique
identifier
NCT06199869.
Keywords:
Eastern
Language: Английский